Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer

Figure 1 Immunohistochemical staining results for NADPH oxidase 2. A: Negative PBS control in gastric cancer; B: Weak expression of NADPH oxidase 2 (NOX2) in gastric cancer, C: Strongly positive expression of NOX2 in gastric cancer, D: Negative expression of NOX2 in adjacent noncancerous tissue (× 200).

Figure 2 Western blot results for NADPH oxidase 2. A: Gastric cancer tissue; B: Adjacent noncancerous tissue. ^aP < 0.05 vs group A.

Figure 3 Localization of NOX2 and CD68 staining. A: NOX2 expression in gastric cancer; B: CD68 expression in gastric cancer (× 200).

Figure 4 Immuohistochemistry staining results for vascular endothelial growth factor and epidermal growth factor receptor in gastric cancer. A: Weakly positive expression of vascular endothelial growth factor (VEGF) in gastric cancer; B: Strongly positive expression of VEGF in gastric cancer; C: Weakly positive expression of epidermal growth factor receptor (EGFR) in gastric cancer; D: Strongly positive expression of EGFR in gastric cancer (× 200).

Figure 5 Expression of NADPH oxidase 2 was positively correlated with vascular endothelial growth factor and epidermal growth factor receptor in gastric cancer. A: Spearman correlation between NOX2 and vascular endothelial growth factor; B: Spearman correlation between NOX2 and epidermal growth factor receptor. VEGF: Vascular endothelial growth factor; EGFR: Epidermal growth factor receptor.

Figure 6 Follow-up investigation of the 5-year survival study showed that the patients who were NADPH oxidase 2 positive clearly presented a worse outcome than the NADPH oxidase 2 negative patients.